Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10517179 | 0.84 | MAOA (0.52) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2833930 | 0.84 | MAOA (0.52) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2125222 | 0.83 | CYP1A2 (0.72) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL9686560 | 0.83 | MAOA (0.50) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6489952 | 0.81 | GPR3 (0.53) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL29175740 | 0.81 | GPR3 (0.53) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6489948 | 0.80 | GPR3 (0.52) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14044130 | 0.79 | CYP1A2 (0.72) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10518195 | 0.79 | MAOA (0.64) | CYP1A2KDM4EMAOAMAOBALDH1A1 | |
| SCHEMBL12630086 | 0.79 | SMN1; SMN2 (0.50) | CYP1A2RXFP1CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-6593324-B2 | P-aminoanilino- derivatives | ORION CORPORATION (FI) | 2003-07-15 | — | — | US | disclosed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | disclosed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | disclosed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | CYP1A2 214/4885RXFP1 62/4885CYP2D6 1632/4885 |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | CYP1A2 214/4885RXFP1 62/4885CYP2D6 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.